JSC Grindeks is awarded for the best investor relations online in the Baltic Countries

JSC Grindeks is awarded for the best investor relations online in the Baltic Countries

05/12/2008

On December 3, in the ceremony The Baltic Market Awards, companies listed in the Nasdaq OMX Baltic Stock exchanges have been announced and awarded as the companies with the best investor relations in 2008. JSC Grindeks was announced and awarded for the best investor relations online in the Baltic Countries.

Publicly available information in English about 68 listed companies has been evaluated for the period from 1 July 2007 to 30 June 2008 within the project The Baltic Market Awards. Companies have been evaluated by more than 100 criteria including quality of annual financial statements and interim statements, company’s reports to the stock exchange, company’s homepage and experts’ evaluation.

Latvian company SAF Tehnika was awarded for the Best investor relations in the Baltic Countries. VST was awarded for The Best Annual Report in the Baltic States, but Eesti Ehitus – For the most visible improvement over the year in the Baltic Countries. Baltika was announced for The best investor relations in Tallinn Stock Exchange, but in the Vilnius Stock exchange – TEO LT.

Evaluation Committee “The Baltic Market Awards” included representatives of the mass media, investors, academics and the Baltic Stock exchanges. The company analysis was conducted by students from the Riga High School of Economics in accordance with the special methods under supervision of the Evaluation Committee and the Baltic Stock Exchanges.

Overview of JSC Grindeks

JSC Grindeks is the leading pharmaceutical company in the Baltic States. Its main activity is research, development, production and sales of original products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups.

A range of Grindeks products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein.

The holding company of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia. It has representatives and representative offices in fourteen countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are the Baltic States, Russia and CIS countries, Japan, the USA. JSC Grindeks shares are listed in the Official List of Riga Stock Exchange.

Contacts:

Laila Kļaviņa
Head of the Communications Department
JSC Grindeks
Phones: +371 67083370, + 371 29256012
e-mail: [email protected]

Related posts

ImgNews4

Grindeks celebrates 75-year anniversary

Today on December 21, JSC Grindeks, the leading pharmaceutical manufacturer in the Baltic States celebrates its 75-year anniversary. Over these 75 years, Grindeks has become...
21/12/2021
magnifiercrossmenu